Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immutep and Lonza Sign Agreement

Published: Wednesday, April 11, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Lonza will initiate process development and cell line selection using Immutep's proprietary cell lines.

Immutep and Lonza have announced an agreement for cell line selection, master cell banking and process development of ImmuFact® IMP321.

Lonza will initiate the process development for Immutep’s lead product, using Immutep's newly-developed proprietary cell lines.

Immutep announced Phase I/II results for IMP321 in an oral presentation at ASCO (American Society of Clinical Oncology conference) in 2010 describing its use in a chemo-immunotherapy protocol in first-line metastatic breast cancer.

“We are pleased to support Immutep’s development initiatives,” said Janet White, head of Lonza development services.

White continued, “This partnership directly reflects Lonza’s commitment to emerging biotechnology innovation through its clinical milestones.”

IMP321 (LAG-3Ig) has potential for the treatment of advanced cancer in combination with standard first-line chemotherapy.

IMP321 is an antigen presenting cell (APC) activator. Tumour-specific memory CD8 T cells are activated by these APC and contribute to tumour regression.

“We have every confidence in Lonza to carry out the production for pivotal trials and beyond,” said Dr. Frederic Triebel, scientific and medical director of Immutep.

Dr. Triebel continued, “The mechanism of action of this synergistic combination of chemotherapy and active immunotherapy is very simple. The chemotherapy provides a burst of tumour cell debris and the surrounding APC take up the tumour antigens. IMP321 activates these APC resulting in a long-lasting CD8 T cell response against the tumour. We think that the combination of first-line standard chemotherapy plus IMP321 should be tested in several first-line indications. We are in partnering discussions at present.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immutep and Eddingpharm Start Production of ImmuFact® IMP321
WuXi AppTec will manufacture ImmuFact® IMP321 to US, European and Chinese GMP standards for Immutep and Eddingpharm.
Tuesday, April 15, 2014
Immutep and GlaxoSmithKline Sign Licence Agreement for IMP731 for the Treatment of Autoimmune Diseases
The licence agreement grants GSK exclusive rights to depleting LAG-3 antibodies including ImmuTune IMP731.
Sunday, January 09, 2011
Immutep and GlaxoSmithKline Sign Licence Agreement for a Novel Therapeutic Antibody for the Treatment of Autoimmune Diseases
Worldwide licence gives GSK exclusive rights to depleting LAG-3 antibodies including ImmuTune IMP731.
Friday, January 07, 2011
Immutep Announces Final Results in Phase I/II Chemoimmunotherapy Trial in Metastatic Breast Cancer
Clinical research paper describes IMP321’s potency in achieving clinical benefit in 90 per cent of patients.
Thursday, September 09, 2010
Immutep Announces Final Results In Phase I/II Chemoimmunotherapy Trial in Breast Cancer
Results reveal that ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer.
Wednesday, January 06, 2010
Immutep Announces Positive Interim Results in Phase I/II Chemoimmunotherapy Trial in Breast Cancer
The ImmuFact IMP321 associated with paclitaxel shows double clinical response rate.
Wednesday, January 07, 2009
Immutep Reports that LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy in Preclinical Studies
Research paper describes increase in potency of a GM-CSF-secreting tumor cell immunotherapy by a LAG-3 fusion protein immunopotentiator.
Friday, June 27, 2008
Soluble LAG-3 Protein is a Prognostic Factor in Breast Cancer
The results pave the way for the testing of a recombinant sLAG-3 protein as an adjuvant therapy for breast cancer in clinical trials.
Wednesday, April 19, 2006
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!